Cargando…

Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer

BACKGROUND: Pathological complete response (pCR) with neoadjuvant chemotherapy (NAC) has been regarded as a surrogate endpoint for disease-free survival (DFS) and overall survival (OS) of patients with breast cancer. No consensus regarding the definition of pCR has been established; there are severa...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukada, Ippei, Araki, Kazuhiro, Kobayashi, Kokoro, Shibayama, Tomoko, Takahashi, Shunji, Horii, Rie, Akiyama, Futoshi, Iwase, Takuji, Ohno, Shinji, Hatake, Kiyohiko, Hozumi, Yasuo, Sata, Naohiro, Ito, Yoshinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025211/
https://www.ncbi.nlm.nih.gov/pubmed/27631393
http://dx.doi.org/10.1371/journal.pone.0162616
_version_ 1782453921355137024
author Fukada, Ippei
Araki, Kazuhiro
Kobayashi, Kokoro
Shibayama, Tomoko
Takahashi, Shunji
Horii, Rie
Akiyama, Futoshi
Iwase, Takuji
Ohno, Shinji
Hatake, Kiyohiko
Hozumi, Yasuo
Sata, Naohiro
Ito, Yoshinori
author_facet Fukada, Ippei
Araki, Kazuhiro
Kobayashi, Kokoro
Shibayama, Tomoko
Takahashi, Shunji
Horii, Rie
Akiyama, Futoshi
Iwase, Takuji
Ohno, Shinji
Hatake, Kiyohiko
Hozumi, Yasuo
Sata, Naohiro
Ito, Yoshinori
author_sort Fukada, Ippei
collection PubMed
description BACKGROUND: Pathological complete response (pCR) with neoadjuvant chemotherapy (NAC) has been regarded as a surrogate endpoint for disease-free survival (DFS) and overall survival (OS) of patients with breast cancer. No consensus regarding the definition of pCR has been established; there are several definitions according to a variety of classifications. Eradication of cancer cells in both breast and lymph nodes has been better associated with improved prognosis than in the breast alone. Even in patients diagnosed as having clinically node-negative cancer before NAC, postoperative pathological examination often shows axillary lymph node metastases. PATIENTS AND METHODS: Of the 771 patients with breast cancer who underwent NAC in the Cancer Institute Hospital between January 2000 and May 2009, 146 patients preoperatively diagnosed as having node-negative breast cancer were retrospectively evaluated. We have made the definition of clinically lymph node-negative (N0) as follows: first, ultrasonography before NAC did not show any lymphadenopathy. Second, a cytological procedure confirmed negative study for each patient when ultrasonography suggested lymphadenopathy. RESULTS: The median observation period was 79.7 months, and the median age of the subjects was 51 years. Pathological examination at the time of the surgery showed lymph node metastases (ypN+) in 46 patients (31.5%). Histological therapeutic effects revealed ypT0/is in 9 patients (6.2%) and ypTinv in 137 (93.8%). Multivariate analysis demonstrated that younger age (49>), large tumor size, NG3, and ypN+ were significant poor prognostic factors for DFS (p = 0.020, p = 0.008, P = 0.022 and p = 0.010, respectively). Moreover, ypN+ was the only significant poor prognostic factor for OS (p = 0.022). The predictive factors of ypN+ in clinically lymph node–negative breast cancer were ypTinv (p = 0.036) and the luminal type (HR+ and HER2-) (p = 0.029). CONCLUSION: The prognosis of clinically lymph node negative breast cancer depended on ypN+, which was associated with ypTinv and luminal subtype.
format Online
Article
Text
id pubmed-5025211
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-50252112016-09-27 Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer Fukada, Ippei Araki, Kazuhiro Kobayashi, Kokoro Shibayama, Tomoko Takahashi, Shunji Horii, Rie Akiyama, Futoshi Iwase, Takuji Ohno, Shinji Hatake, Kiyohiko Hozumi, Yasuo Sata, Naohiro Ito, Yoshinori PLoS One Research Article BACKGROUND: Pathological complete response (pCR) with neoadjuvant chemotherapy (NAC) has been regarded as a surrogate endpoint for disease-free survival (DFS) and overall survival (OS) of patients with breast cancer. No consensus regarding the definition of pCR has been established; there are several definitions according to a variety of classifications. Eradication of cancer cells in both breast and lymph nodes has been better associated with improved prognosis than in the breast alone. Even in patients diagnosed as having clinically node-negative cancer before NAC, postoperative pathological examination often shows axillary lymph node metastases. PATIENTS AND METHODS: Of the 771 patients with breast cancer who underwent NAC in the Cancer Institute Hospital between January 2000 and May 2009, 146 patients preoperatively diagnosed as having node-negative breast cancer were retrospectively evaluated. We have made the definition of clinically lymph node-negative (N0) as follows: first, ultrasonography before NAC did not show any lymphadenopathy. Second, a cytological procedure confirmed negative study for each patient when ultrasonography suggested lymphadenopathy. RESULTS: The median observation period was 79.7 months, and the median age of the subjects was 51 years. Pathological examination at the time of the surgery showed lymph node metastases (ypN+) in 46 patients (31.5%). Histological therapeutic effects revealed ypT0/is in 9 patients (6.2%) and ypTinv in 137 (93.8%). Multivariate analysis demonstrated that younger age (49>), large tumor size, NG3, and ypN+ were significant poor prognostic factors for DFS (p = 0.020, p = 0.008, P = 0.022 and p = 0.010, respectively). Moreover, ypN+ was the only significant poor prognostic factor for OS (p = 0.022). The predictive factors of ypN+ in clinically lymph node–negative breast cancer were ypTinv (p = 0.036) and the luminal type (HR+ and HER2-) (p = 0.029). CONCLUSION: The prognosis of clinically lymph node negative breast cancer depended on ypN+, which was associated with ypTinv and luminal subtype. Public Library of Science 2016-09-15 /pmc/articles/PMC5025211/ /pubmed/27631393 http://dx.doi.org/10.1371/journal.pone.0162616 Text en © 2016 Fukada et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Fukada, Ippei
Araki, Kazuhiro
Kobayashi, Kokoro
Shibayama, Tomoko
Takahashi, Shunji
Horii, Rie
Akiyama, Futoshi
Iwase, Takuji
Ohno, Shinji
Hatake, Kiyohiko
Hozumi, Yasuo
Sata, Naohiro
Ito, Yoshinori
Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer
title Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer
title_full Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer
title_fullStr Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer
title_full_unstemmed Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer
title_short Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer
title_sort predictive factors and value of ypn+ after neoadjuvant chemotherapy in clinically lymph node-negative breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025211/
https://www.ncbi.nlm.nih.gov/pubmed/27631393
http://dx.doi.org/10.1371/journal.pone.0162616
work_keys_str_mv AT fukadaippei predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer
AT arakikazuhiro predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer
AT kobayashikokoro predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer
AT shibayamatomoko predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer
AT takahashishunji predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer
AT horiirie predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer
AT akiyamafutoshi predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer
AT iwasetakuji predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer
AT ohnoshinji predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer
AT hatakekiyohiko predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer
AT hozumiyasuo predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer
AT satanaohiro predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer
AT itoyoshinori predictivefactorsandvalueofypnafterneoadjuvantchemotherapyinclinicallylymphnodenegativebreastcancer